| Assessment Status |
Rapid Review Complete |
| HTA ID |
24026 |
| Drug |
Pemigatinib |
| Brand |
Pemazyre® |
| Indication |
Pemigatinib (Pemazyre®) is indicated for the treatment of adults with locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or rearrangement that have progressed after at least one prior line of systemic therapy. |
| Rapid review commissioned |
05/07/2024 |
| Rapid review completed |
16/07/2024 |
| Rapid review outcome |
A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of pemigatinib compared with the current standard-of-care, on the basis of the proposed price relative to currently available therapies. |
